MIGLITOL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C8H17NO5
Molecular Weight	207.2243
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO

InChI

InChIKey=IBAQFPQHRJAVAV-ULAWRXDQSA-N

InChI=1S/C8H17NO5/c10-2-1-9-3-6(12)8(14)7(13)5(9)4-11/h5-8,10-14H,1-4H2/t5-,6+,7-,8-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C8H17NO5
Molecular Weight	207.2243
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.drugbank.ca/drugs/DB00491
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/cdi/miglitol.html

Miglitol, an oral alpha-glucosidase inhibitor, is a desoxynojirimycin derivative that delays the digestion of ingested carbohydrates, thereby resulting in a smaller rise in blood glucose concentration following meals. As a consequence of plasma glucose reduction, miglitol reduce levels of glycosylated hemoglobin in patients with Type II (non-insulin-dependent) diabetes mellitus. Systemic nonenzymatic protein glycosylation, as reflected by levels of glycosylated hemoglobin, is a function of average blood glucose concentration over time. Because its mechanism of action is different, the effect of miglitol to enhance glycemic control is additive to that of sulfonylureas when used in combination. In addition, miglitol diminishes the insulinotropic and weight-increasing effects of sulfonylureas. Miglitol has minor inhibitory activity against lactase and consequently, at the recommended doses, would not be expected to induce lactose intolerance. In contrast to sulfonylureas, miglitol does not enhance insulin secretion. The antihyperglycemic action of miglitol results from a reversible inhibition of membrane-bound intestinal a-glucoside hydrolase enzymes. Membrane-bound intestinal a-glucosidases hydrolyze oligosaccharides and disaccharides to glucose and other monosaccharides in the brush border of the small intestine. In diabetic patients, this enzyme inhibition results in delayed glucose absorption and lowering of postprandial hyperglycemia. Miglitol is used as an adjunct to diet to improve glycemic control in patients with non-insulin-dependent diabetes mellitus (NIDDM) whose hyperglycemia cannot be managed with diet alone.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Maltase-glucoamylase 9 Target ID: CHEMBL2074 Sources: http://www.drugbank.ca/drugs/DB00491	Antagonist 2849	6.0 µM [IC50]
Lysosomal alpha-glucosidase 9 Target ID: CHEMBL2608 Sources: http://www.drugbank.ca/drugs/DB00491	Antagonist 2849	2.0 nM [IC50]
Neutral alpha-glucosidase AB 1 Target ID: CHEMBL2519 Sources: http://www.drugbank.ca/drugs/DB00491	Antagonist 2849
Neutral alpha-glucosidase C 1 Target ID: CHEMBL2520 Sources: http://www.drugbank.ca/drugs/DB00491	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 262 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf	Primary		Approved 8583	GLYSET Approved Use GLYSET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Launch Date 1996

C_max

Value	Dose	Co-administered	Analyte	Population
0.78 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/10776834/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: SUCROSE	SUCROSE	MIGLITOL plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
1.22 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/10776834/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		MIGLITOL plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
1.86 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/10776834/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		MIGLITOL plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
2.61 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/10776834/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		MIGLITOL plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
7.08 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/10776834/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		MIGLITOL plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
11.02 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/10776834/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		MIGLITOL plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
2.23 h REVIEW https://pubmed.ncbi.nlm.nih.gov/10776834/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	MIGLITOL plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
2.36 h REVIEW https://pubmed.ncbi.nlm.nih.gov/10776834/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	MIGLITOL plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
2 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf	100 mg 3 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MIGLITOL plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
75 mg 3 times / day multiple, oral Recommended Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20558922/	healthy, 39.3 Health Status: healthy Age Group: 39.3 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/20558922/	Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea (severe, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/20558922/
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20963449/	unhealthy, 58.4 Health Status: unhealthy Age Group: 58.4 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/20963449/	Other AEs: Abdominal discomfort, Diarrhea... Other AEs: Abdominal discomfort (26.95%) Diarrhea (33.9%) Hypoglycemia (33.9%) Sources: https://pubmed.ncbi.nlm.nih.gov/20963449/
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf	Other AEs: Abdominal pain, Diarrhea... Other AEs: Abdominal pain (11.7%) Diarrhea (28.7%) Flatulence (41.5%) Skin rash (4.3%) Serum iron decreased (9.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf

AEs

AE	Significance	Dose	Population
Diarrhea	severe, 1 patient Disc. AE	75 mg 3 times / day multiple, oral Recommended Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20558922/	healthy, 39.3 Health Status: healthy Age Group: 39.3 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/20558922/
Abdominal discomfort	26.95%	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20963449/	unhealthy, 58.4 Health Status: unhealthy Age Group: 58.4 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/20963449/
Diarrhea	33.9%	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20963449/	unhealthy, 58.4 Health Status: unhealthy Age Group: 58.4 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/20963449/
Hypoglycemia	33.9%	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20963449/	unhealthy, 58.4 Health Status: unhealthy Age Group: 58.4 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/20963449/
Abdominal pain	11.7%	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf
Diarrhea	28.7%	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf
Skin rash	4.3%	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf
Flatulence	41.5%	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf
Serum iron decreased	9.2%	100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf

Sourcing

Vendor/Aggregator	ID	URL
3A SpeedChemical Inc	SP-13673	http://www.speedchemical.com/products2_id_4791.html
3B Scientific (Wuhan) Corp	3B2-1030	http://www.3bsc.com/index/pro_info.php?id=41935
abcr GmbH	AB474562	http://www.abcr.com/shop/en/AB474562
AbMole Bioscience	M5788	http://www.abmole.com/products/miglitol.html
Achemtek	0104-014966	http://www.achemtek.com/72432-03-2
Acorn PharmaTech	ACN-040712	http://www.acornpharmatech.com/
Adooq BioScience	A11678	https://www.adooq.com/miglitol-glyset.html
AHH Chemical co.,ltd	MT-54302	http://www.ahhchemical.com/product/MT-54302.html
AK Scientific, Inc. (AKSCI)	K230	http://www.aksci.com/item_detail.php?cat=K230
AK Scientific, Inc. (AKSCI)	SYN3027	http://www.aksci.com/item_detail.php?cat=SYN3027
Alfa Chemistry	AP72432032	https://reagents.alfa-chemistry.com/product/miglitol-cas-72432-03-2-15598.html
ApexBio Technology	B2072	http://www.apexbt.com/acipimox-28867.html
ApexBio Technology	B2111	http://www.apexbt.com/miglitol.html
Aurora Fine Chemicals LLC	A13.142.526	http://online.aurorafinechemicals.com/info?ID=A13.142.526
Aurum Pharmatech LLC	NE45506	http://www.Aurumpharmatech.com/Product/ProductDetails/NE45506
AvaChem Scientific	3965	http://www.avachem.com/productSearch.asp?3965
Avantor Inc	100571-486	https://us.vwr.com/store/catalog/product.jsp?catalog_number=100571-486
Axon MedChem	2067	https://www.axonmedchem.com/product/2067
BioCrick	BCC4921	http://www.biocrick.com/Miglitol-BCC4921.html
BioSynth	W-104490	https://www.biosynth.com/en/products/life-science/enzyme-substrates-reagents/products/W-104490.html
BLD Pharm	BD10759	http://www.bldpharm.com/products/72432-03-2.html
Capot Chemical	21444	http://www.capotchem.com/en/21444.htm
Capot Chemical	6069	http://www.capotchem.com/en/6069.htm
Capot Chemical	PubChem21444	http://www.capotchem.com/en/21444.htm
Capot Chemical	PubChem6069	http://www.capotchem.com/en/6069.htm
Chem Scene	CS-2596	http://www.chemscene.com/72432-03-2.html
ChemMol	96708110	http://www.chemmol.com/chemmol/96708110.html
Chemspace	CSSB00000693958	https://chem-space.com/CSSB00000693958
Chiralblock Biosciences	CB10422	http://www.chiralblock.com/products/72432-03-2.html
Clearsynth	CS-O-11693	http://www.clearsynth.com/en/CSO11693.html
Combi-Blocks	OR-4651	http://www.combi-blocks.com/cgi-bin/find.cgi?OR-4651
CSNpharm	CSN10130	https://www.csnpharm.com/products/miglitol.html
DC Chemicals	DCAPI1324	http://www.dcchemicals.com//product_show-Miglitol_Glyset_.html
Enamine	Z1541638520	https://www.enaminestore.com/catalog/Z1541638520
Glentham Life Sciences	GC9049	http://www.glentham.com/products/product/GC9049/
Hairui	HR137204	http://www.hairuichem.com/en/product/72432-03-2.html
iChemical	EBD36555	http://www.ichemical.com/products/72432-03-2.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN01324899	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01324899
mcule	MCULE-2158237443	https://mcule.com/MCULE-2158237443/
MedChem Express	HY-B0481	https://www.medchemexpress.com/Miglitol.html
MuseChem	A000308	https://www.musechem.com/product/A000308.html
OChem	4279	http://www.ocheminc.com/index.php?act=psearch&pid=432M032
Renno Tech	RL04761	http://www.rennotech.com/product_show.asp?id=5010
Smolecule	S535439	http://www.smolecule.com/products/s535439
TCI (Tokyo Chemical Industry)	M2302	http://www.tcichemicals.com/eshop/en/us/commodity/M2302/index.html
THE BioTek	bt-276372	https://www.thebiotek.com/product/inhibitors/bt-276372
Tocris	4985	https://www.tocris.com/products/miglitol_4985
Yuhao Chemical	LX2647	http://www.chemyuhao.com/72432-03-2.html

PubMed

Title	Date	PubMed
The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus.	2010-12	20667563
Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.	2010-11	20682680
Changes in α-glucosidase activities along the jejunal-ileal axis of normal rats by the α-glucosidase inhibitor miglitol.	2010-10	20153003
Antioxidant rich grape pomace extract suppresses postprandial hyperglycemia in diabetic mice by specifically inhibiting alpha-glucosidase.	2010-08-27	20799969
Recommendations for management of diabetes during Ramadan: update 2010.	2010-08	20668157
The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis.	2010-08	20484130
Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -.	2010-07	20519875
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.	2010-06	20412332
Computational identification of uncharacterized cruzain binding sites.	2010-05-11	20485483
A case of insulinoma following total gastrectomy--effects of an alpha-glucosidase inhibitor on suppressing GIP and GLP-1 elevations.	2010-04	20122751
Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk.	2010-03-24	20448799
Glucose supply and insulin demand dynamics of antidiabetic agents.	2010-03-01	20307399
Disordered eating behavior in individuals with diabetes: importance of context, evaluation, and classification.	2010-03	20190297
New glucosidase inhibitors from an ayurvedic herbal treatment for type 2 diabetes: structures and inhibition of human intestinal maltase-glucoamylase with compounds from Salacia reticulata.	2010-01-26	20039683
Glycosidase inhibition: assessing mimicry of the transition state.	2010-01-21	20066263
Aspects of insulin treatment.	2010-01	20040659
Pneumatosis cystoides intestinalis induced by the α-glucosidase inhibitor miglitol.	2010	20686288
Comparison of adverse gastrointestinal effects of acarbose and miglitol in healthy men: a crossover study.	2010	20558922
Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men.	2010	20519807
Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.	2010	20519806
Acute metabolic responses to a high-carbohydrate meal in outpatients with type 2 diabetes treated with a low-carbohydrate diet: a crossover meal tolerance study.	2009-12-29	20040075
The alpha-glucosidase inhibitor miglitol delays the development of diabetes and dysfunctional insulin secretion in pancreatic beta-cells in OLETF rats.	2009-12-10	19818342
Drugs associated with more suicidal ideations are also associated with more suicide attempts.	2009-10-02	19798416
Amplification of the inhibitory activity of miglitol by monofluorination.	2009-10-01	19700320
Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels.	2009-10-01	19563873
Pneumatosis cystoides intestinalis of the ascending colon related to acarbose treatment: a case report.	2009-09-08	19918292
Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo.	2009-09-05	19732457
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.	2009-07-20	19619327
Suppressive response of confections containing the extractive from leaves of Morus Alba on postprandial blood glucose and insulin in healthy human subjects.	2009-07-14	19602243
The alpha-glucosidase inhibitor miglitol suppresses postprandial hyperglycaemia and interleukin-1beta and tumour necrosis factor-alpha gene expression in rat peripheral leucocytes induced by intermittent sucrose loading.	2009-07	19138443
Hypoglycemic herbs and their action mechanisms.	2009-06-12	19523223
The alpha-glucosidase inhibitor miglitol decreases glucose fluctuations and gene expression of inflammatory cytokines induced by hyperglycemia in peripheral leukocytes.	2009-06	19216056
Effects of a low-carbohydrate diet on glycemic control in outpatients with severe type 2 diabetes.	2009-05-06	19419563
Postprandial hyperglycemia as an etiological factor in vascular failure.	2009-04-29	19402896
Diabetes treatment.	2009-03	19246581
Effect of miglitol, an alpha-glucosidase inhibitor, on atherogenic outcomes in balloon-injured diabetic rats.	2009-03	19085811
Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients.	2009-02	19236625
Rapid quantification of miglustat in human plasma and cerebrospinal fluid by liquid chromatography coupled with tandem mass spectrometry.	2009-01-15	19095507
Effect of insulin-unstimulated diabetic therapy with miglitol on serum cystatin C level and its clinical significance.	2009-01	19027977
Postprandial hypoglycemic effect of mulberry leaf in Goto-Kakizaki rats and counterpart control Wistar rats.	2009	20098579
Synthesis of iminoalditol analogues of galactofuranosides and their activities against glycosidases.	2008-11-24	18706536
Comparison of pre- vs. postmeal administration of miglitol for 3 months in type 2 diabetic patients.	2008-09	18721256
Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.	2008-09	18702958
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.	2008-08-01	18595718
Alpha-glucosidase-like activity detected in a siboglinid polychaete, Oligobrachia mashikoi.	2008-04	18459818
Effect of butanol fraction from Cassia tora L. seeds on glycemic control and insulin secretion in diabetic rats.	2008	20016725
Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes.	2008	19337532
Evaluation of the efficacy, safety and tolerability of miglitol in adult Indian patients with uncomplicated type 2 diabetes mellitus.	2007-06	18232183
Indian herbs and herbal drugs used for the treatment of diabetes.	2007-05	18398493
Hypoglycemic and hypolipidemic effects of Saururus chinensis Baill in streptozotocin-induced diabetic rats.	2007	20535394

Patents

Sample Use Guides

In Vivo Use Guide

Initial dose: 25 mg orally 3 times a day -After 4 to 8 weeks, may increase to 50 mg orally 3 times a day if needed; after 3 more months, may increase to 100 mg orally 3 times a day if needed based on glycosylated hemoglobin Maintenance dose: 50 mg to 100 mg orally 3 times a day Maximum dose: 100 mg orally 3 times a day

Route of Administration: Oral

In Vitro Use Guide

Miglitol at high concentrations (20-200 uM) inhibited considerably trehalase and lactase (a beta-galactosidase) activities in rat small intestine.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:56:34 GMT 2025` Edited by `admin` on `Mon Mar 31 17:56:34 GMT 2025`
Record UNII	0V5436JAQW
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GLYSET

Preferred Name

English

MIGLITOL

Official Name

English

MIGLITOL [VANDF]

Common Name

English

NSC-758702

Code

English

MIGLITOL [MART.]

Common Name

English

3,4,5-PIPERIDINETRIOL, 1-(2-HYDROXYETHYL)-2-(HYDROXYMETHYL)-, (2R-(2.ALPHA.,3.BETA.,4.ALPHA.,5.BETA.))-

Common Name

English

BAY M 1099

Code

English

MIGLITOL [JAN]

Common Name

English

BAY-M-1099

Code

English

miglitol [INN]

Common Name

English

MIGLITOL [USAN]

Common Name

English

MIGLITOL [ORANGE BOOK]

Common Name

English

MIGLITOL [MI]

Common Name

English

(2R,3R,4R,5S)-1-(2-Hydroxyethyl)-2-(hydroxymethyl)-3,4,5-piperidinetriol

Systematic Name

English

Miglitol [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QA10BF02